Vanguard Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,821,537
| Closed | -$288M | – | 4573 |
|
|
2023
Q2 | $288M | Buy |
2,821,537
+70,596
| +3% | +$6.68M | 0.01% | 1269 |
|
|
2023
Q1 | $250M | Buy |
2,750,941
+45,285
| +2% | +$2.66M | 0.01% | 1332 |
|
|
2022
Q4 | $103M | Buy |
2,705,656
+52,356
| +2% | +$1.8M | ﹤0.01% | 1792 |
|
|
2022
Q3 | $66.7M | Buy |
2,653,300
+33,890
| +1% | +$939K | ﹤0.01% | 2039 |
|
|
2022
Q2 | $79.6M | Sell |
2,619,410
-23,672
| -0.9% | -$706K | ﹤0.01% | 1952 |
|
|
2022
Q1 | $86.6M | Buy |
2,643,082
+85,409
| +3% | +$2.53M | ﹤0.01% | 2026 |
|
|
2021
Q4 | $67.4M | Buy |
2,557,673
+17,183
| +0.7% | +$1.33M | ﹤0.01% | 2185 |
|
|
2021
Q3 | $256M | Buy |
2,540,490
+1,930
| +0.1% | +$226K | 0.01% | 1445 |
|
|
2021
Q2 | $359M | Buy |
2,538,560
+104,061
| +4% | +$11.8M | 0.01% | 1222 |
|
|
2021
Q1 | $243M | Buy |
2,434,499
+114,468
| +5% | +$13.4M | 0.01% | 1472 |
|
|
2020
Q4 | $287M | Buy |
2,320,031
+205,934
| +10% | +$27.1M | 0.01% | 1230 |
|
|
2020
Q3 | $206M | Sell |
2,114,097
-89,454
| -4% | -$11.2M | 0.01% | 1261 |
|
|
2020
Q2 | $344M | Sell |
2,203,551
-36,177
| -2% | -$5.5M | 0.01% | 946 |
|
|
2020
Q1 | $323M | Buy |
2,239,728
+72,842
| +3% | +$14.1M | 0.01% | 866 |
|
|
2019
Q4 | $443M | Buy |
2,166,886
+335,461
| +18% | +$61.2M | 0.02% | 885 |
|
|
2019
Q3 | $147M | Buy |
1,831,425
+81,974
| +5% | +$6.96M | 0.01% | 1518 |
|
|
2019
Q2 | $165M | Buy |
1,749,451
+64,609
| +4% | +$5.58M | 0.01% | 1471 |
|
|
2019
Q1 | $144M | Buy |
1,684,842
+426,608
| +34% | +$35.4M | 0.01% | 1547 |
|
|
2018
Q4 | $70.6M | Buy |
1,258,234
+70,602
| +6% | +$4.31M | ﹤0.01% | 1853 |
|
|
2018
Q3 | $97.1M | Buy |
1,187,632
+509,326
| +75% | +$35.9M | ﹤0.01% | 1818 |
|
|
2018
Q2 | $23.7M | Buy |
678,306
+53,632
| +9% | +$1.63M | ﹤0.01% | 2496 |
|
|
2018
Q1 | $12.8M | Buy |
624,674
+12,032
| +2% | +$310K | ﹤0.01% | 2702 |
|
|
2017
Q4 | $17.3M | Buy |
612,642
+96,196
| +19% | +$2.68M | ﹤0.01% | 2540 |
|
|
2017
Q3 | $16.1M | Buy |
516,446
+220,906
| +75% | +$6.64M | ﹤0.01% | 2584 |
|
|
2017
Q2 | $9.35M | Buy |
295,540
+154,515
| +110% | +$3.8M | ﹤0.01% | 2812 |
|
|
2017
Q1 | $3.19M | Sell |
141,025
-1,855
| -1% | -$45.8K | ﹤0.01% | 3225 |
|
|
2016
Q4 | $3.12M | Buy |
142,880
+15,482
| +12% | +$392K | ﹤0.01% | 3211 |
|
|
2016
Q3 | $3.36M | Buy |
127,398
+79,483
| +166% | +$1.58M | ﹤0.01% | 3178 |
|
|
2016
Q2 | $946K | Buy |
+47,915
| New | +$931K | ﹤0.01% | 3616 |
|
Other funds holding RETA
Vanguard Group's RETA Position: Q3 2023 in Review
Vanguard Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,821,537 shares — an estimated $288M sold.
Vanguard Group first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $443M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Vanguard Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Vanguard Group sold 2,821,537 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $288M.
- Vanguard Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Vanguard Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $443M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.